GeneVax

Executive Summary

GeneVax is a preclinical-stage biotechnology company pioneering gene-based vaccines and immunotherapies for infectious diseases and oncology. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company leverages advanced delivery systems and rational antigen design to elicit potent and durable immune responses. Its platform aims to overcome limitations of traditional vaccines by enabling rapid development and strong T-cell immunity. GeneVax has raised $160 million to date from prominent investors, supporting its pipeline of prophylactic vaccines and cancer immunotherapies. The company's lead candidate targets a major infectious disease, with IND-enabling studies underway. A Phase I trial is expected to initiate in 2027. In oncology, GeneVax is advancing a novel gene-based immunotherapy designed to stimulate anti-tumor immunity. While still preclinical, the company's robust financial backing and experienced management team position it well for key milestones. Successful proof-of-concept data and regulatory progress could unlock significant value, though early-stage risks remain. The upcoming catalysts include clinical trial initiation, preclinical data readouts, and potential partnership opportunities.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase I clinical trial for lead infectious disease vaccine candidate65% success
• Q4 2026Preclinical proof-of-concept data for lead oncology immunotherapy candidate70% success
• Q3 2027Potential partnership or licensing deal for gene-based platform technology40% success